New Lung Cancer Drug Targets HER2 Mutations
Adults with HER2-mutant advanced lung cancer gain a new first-line oral option approved in China.
Updated on Nov. 5, 2026 in Cancer
China's National Medical Products Administration (NMPA) granted marketing authorization to Bayer's sevabertinib as a first-line treatment for adults with unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying HER2 activating mutations. The approval follows a September U.S. accelerated approval for the same first-line use, and affects patients whose tumors carry these specific mutations.
Why it matters
HER2 activating mutations occur in only about 2% to 4% of patients with advanced NSCLC, so the change applies to a narrow, genetically defined group rather than most lung cancer patients. For that group, it adds a targeted oral option at the first line of treatment, where choices have been limited.
The first-line approval rests on a single-arm phase I/II trial, SOHO-01, in 73 treatment-naive patients, which reported a 75% objective response rate without a control group. Regulators have flagged that continued approval for this use may depend on the randomized phase III SOHO-02 trial confirming clinical benefit.
The players
Bayer
Global pharmaceutical company with a major oncology portfolio, developer of sevabertinib.
National Medical Products Administration (NMPA)
China's national regulator responsible for approving medicines, including this first-line lung cancer therapy.
U.S. Food and Drug Administration (FDA)
The U.S. agency that grants drug approvals and granted accelerated approval for sevabertinib's first-line use in September.
The details
Sevabertinib is an oral, reversible small-molecule tyrosine kinase inhibitor. It blocks specific tyrosine kinases that drive the growth of cancer cells, and it potently inhibits mutant HER2, including HER2 exon 20 insertions and HER2 point mutations. The Chinese approval covers patients whose tumors carry HER2 activating mutations and who have not yet received systemic therapy for advanced disease.
Timeline
Earlier in 2026: NMPA approved sevabertinib as monotherapy for patients who had received one prior systemic therapy.
August 2026: Japan's Ministry of Health, Labour, and Welfare approved sevabertinib for HER2-mutant NSCLC.
September 2026: The U.S. FDA granted accelerated approval for sevabertinib as first-line treatment.
November 5, 2026: Bayer announced the NMPA's first-line marketing authorization in China.
Health Landscape
Sevabertinib extends a targeted HER2 approach that regulators first cleared for patients who had already received systemic therapy, moving it earlier in the treatment sequence. Targeted oral therapies for genetically defined lung cancer subsets have steadily reshaped first-line care for those patients.
If you have been diagnosed with advanced lung cancer, ask your oncologist whether HER2 mutation testing has been done on your tumor, since that determines eligibility for this drug class. Because HER2 mutations are uncommon, this approval mainly matters to the small share of patients whose tumors test positive.
The takeaway
Targeted therapies depend on finding the right molecular marker, so testing for HER2 mutations in advanced lung cancer is a key question to raise with a specialist. Watch for phase III results from SOHO-02, which will determine whether this first-line use stays approved over time.
What happens next
Continued first-line approval may depend on results from the ongoing phase III SOHO-02 trial, which has no reported date in the source.
Further reading
Explore more on Cancer to see how targeted therapies are changing treatment for lung cancer.
